Distemper-Adeno-Parvo

Verify with FDA CVM →

32 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
32
Total Reports
3
Deaths Reported
940.0%
Death Rate

Active Ingredients

Distemper-Adeno-Parvo

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 32

Most Affected Breeds

Terrier - Yorkshire 4
Terrier - Bull - American Pit 4
Retriever - Golden 3
Retriever - Labrador 2
Siberian Husky 2
Chihuahua 2
Terrier (unspecified) 2
Hound - Basset 2
Shih Tzu 2
Boxer (German Boxer) 2

Most Reported Reactions

Vomiting 19
Lethargy (see also Central nervous system depression in 'Neurological') 9
Anaphylaxis 6
Facial swelling (see also 'Skin') 5
Hives (see also 'Skin') 5
Pale mucous membrane 5
Ataxia 4
Decreased appetite 4
Fever 3
Panting 3
Breathing difficulty 3
Pulmonary oedema 3

Outcome Breakdown

Recovered/Normal
14 (43.8%)
Ongoing
13 (40.6%)
Outcome Unknown
2 (6.3%)
Died
2 (6.3%)
Euthanized
1 (3.1%)

Data Summary

Metric Value
Total adverse event reports 32
Reports involving death 3
Case-fatality rate (reported events) 940.0%
Distinct species in reports 1
Distinct breeds in reports 17
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Distemper-Adeno-Parvo Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 32 adverse event reports referencing Distemper-Adeno-Parvo, including 3 reports in which the animal died — a 940.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Distemper-Adeno-Parvo. Reported administration routes include Subcutaneous, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Distemper-Adeno-Parvo reports are Dog (32 reports), with Dog accounting for the largest share. Within those species, Terrier - Yorkshire (4), Terrier - Bull - American Pit (4), Retriever - Golden (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Distemper-Adeno-Parvo are Vomiting (19), Lethargy (see also Central nervous system depression in 'Neurological') (9), Anaphylaxis (6), Facial swelling (see also 'Skin') (5). Of the 32 reports with a coded outcome, Recovered/Normal is the leading category at 43.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Distemper-Adeno-Parvo.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial